Viridian (VRDN) Director Christopher Cain Receives Option Award

What Happened

• Christopher W. Cain, a member of Viridian Therapeutics' board of directors, was granted a derivative award (option) covering 32,341 shares on July 1, 2026. The transaction is reported as an award/acquisition (code A) at $0.00 cash paid at grant; no immediate purchase or sale occurred.

Key Details

• Transaction date: 2026-07-01; filing date: 2026-07-02 (timely).
• Instrument: derivative award (option) covering 32,341 shares; reported price $0.00 at grant.
• Vesting: the option vests in full on the earlier of (i) July 1, 2027 or (ii) Viridian’s 2027 annual meeting, subject to Cain’s continued Board service (Footnote 1).
• Beneficial ownership: Cain holds the option for one or more investment vehicles managed by Fairmount Funds Management LLC and disclaims beneficial ownership; any net cash or stock from the option is turned over to the Adviser (Footnote 2).
• Shares owned after transaction: not specified in this filing.

Context

• This is a standard director compensation grant rather than an open-market purchase or sale; awards are common and do not by themselves signal a director buying shares outright. The award is a derivative that vests based on continued service and a date/meeting condition.